跳至主要内容
临床试验/NCT05743543
NCT05743543
已完成
早期 1 期

A Feasibility Study of a Sphenopalatine Ganglion (SPG) Block for Post Traumatic Stress Disorder (PTSD)

New York State Psychiatric Institute1 个研究点 分布在 1 个国家目标入组 6 人2019年5月28日

概览

阶段
早期 1 期
干预措施
未指定
疾病 / 适应症
Post Traumatic Stress Disorder
发起方
New York State Psychiatric Institute
入组人数
6
试验地点
1
主要终点
tolerability: number of adverse events
状态
已完成
最后更新
2年前

概览

简要总结

Some patients with Post Traumatic Stress Disorder (PTSD) respond only partially to medication. This study is a pilot study investigating whether blocking the SPG helps reduce the symptoms of PTSD. This study does not involve treatment with medications. It is a proof of principal study.

详细描述

The sphenopalatine ganglion (SPG) is a collection of neurons involved in autonomic regulation (which refers to bodily processes that are automatic like heart rate and blood pressure). Blocking the SPG is used to treat disorders, such as migraines or cluster headaches (short, severe headaches that occur together). The procedure will be performed by a doctor who specializes in ear, nose throat surgery. The block consists of the injection of a numbing agent (similar to the type used by dentists) to the SPG. After the SPG block, we will follow patients for 8 weeks to see how they feel.

注册库
clinicaltrials.gov
开始日期
2019年5月28日
结束日期
2023年6月1日
最后更新
2年前
研究类型
Interventional
研究设计
Single Group
性别
All

研究者

责任方
Principal Investigator
主要研究者

Diana Martinez

Clinical professor in Psychiatry

New York State Psychiatric Institute

入排标准

入选标准

  • Participants with a principal diagnosis of PTSD on stable dose of psychiatric medication or in stable psychotherapy for at least 3 months, who experience residual symptoms.
  • Participants who understand all study procedures and can undergo informed consent

排除标准

  • Participants with a medical disorder, for whom study participation could be deleterious (neurologic, cardiac, renal or infectious disease)
  • Pregnant or breast feeding participants
  • Participants who are on an anticoagulant, such as warfarin, or otherwise have a medical condition that increases bleeding risk

结局指标

主要结局

tolerability: number of adverse events

时间窗: 8 weeks

tolerability: number of adverse events

feasibility: number of participants completing the 8-week study

时间窗: 8 weeks

feasibility: number of participants completing the 8-week study

研究点 (1)

Loading locations...

相似试验